Conditions: Age Related Macular Degeneration (AMD) Macular Degeneration Choroidal Neovascularization (CNV)
Keywords: neovascular age related macular degeneration choroidal neovascularization
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 288
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine the benefits of treating subjects with neovascular age-related macular degeneration (AMD) at an earlier stage of choroidal neovascularization (CNV) as compared to those with established CNV. Additionally, the study would like to determine the efficacy of Macugen in preserving visual function in those subjects having CNV secondary to neovascular AMD.

Detailed description:
A decision was made by the sponsor (08 May 2009) to terminate this study early; the study had achieved the primary objective prior to termination. This study was not terminated due to safety reasons.

Arms:
arm 1: None

Interventions: intervention 1: Pegaptanib Sodium 0.3 mg
Intervention descriptions: intervention 1: Pegaptanib Sodium dosed every 6 weeks in affected eye.

Protocol document: